Get the Stockscreener App
1.51
0.67%
0.02
Sellas Life Sciences Group Inc stock is traded at $1.51, with a volume of 808.35K.
It is up +0.67% in the last 24 hours and up +38.89% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$1.49
Open:
$1.49
24h Volume:
808.35K
Relative Volume:
0.33
Market Cap:
$117.07M
Revenue:
-
Net Income/Loss:
$-37.34M
P/E Ratio:
-1.1103
EPS:
-1.36
Net Cash Flow:
$-36.91M
1W Performance:
+22.95%
1M Performance:
+38.89%
6M Performance:
+29.31%
1Y Performance:
+147.81%
1-Day Range:
$1.45
$1.54
1-Week Range:
$1.235
$1.84
52-Week Range:
$0.59
$1.84
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.515 | 117.07M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.18 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
711.24 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
668.58 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.94 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.19 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
Insider’s View: Deciphering SELLAS Life Sciences Group Inc (SLS)’s Financial Health Through Ratios - The Dwinnex
Market Analysts see SELLAS Life Sciences Group Inc [SLS] gaining to $18. Time to buy? - The DBT News
SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS) - Defense World
Investors Buy High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS) - MarketBeat
SELLAS Life Sciences Group Target of Unusually High Options Trading (NASDAQ:SLS) - MarketBeat
You Should Read This Analysis Before Investing in SELLAS Life Sciences Group Inc (NASDAQ:SLS) - US Post News
Sellas Life Sciences Group Announces $25 Million Registered Direct Offering - Defense World
Analysts Provide An Important Insights On SELLAS Life Sciences Group Inc (SLS) - Stocks Register
SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow
Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL
SELLAS secures $25 million in registered direct offering By Investing.com - Investing.com South Africa
SELLAS secures $25 million in registered direct offering - MSN
SELLAS Life Sciences Group Announces $25 Million Registered - GlobeNewswire
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - Defense World
SELLAS Life Sciences Announces Positive Phase 3 Trial Results - TipRanks
SELLAS Life Sciences stock falls on GPS data (SLS:NASDAQ) - Seeking Alpha
SELLAS Life Sciences Announces Positive Outcome of Interim - GlobeNewswire
SELLAS Phase 3 AML Trial Shows Promising 13.5-Month Survival Data, Double Historical Average - StockTitan
SLS Stock Quote Price and Forecast - CNN
SELLAS Life Sciences amends executive severance agreements - MSN
SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - Defense World
SELLAS Life Sciences Group Inc (NASDAQ: SLS): Blank Check On Growth? - Stocks Register
SELLAS Life Sciences Group Approves Amendments to Change in Control Severance Agreements - Defense World
SELLAS Life Sciences amends executive severance agreements By Investing.com - Investing.com Australia
SELLAS Life Sciences Amends Severance for Key Executives - TipRanks
Analyze SELLAS Life Sciences Group Inc (NASDAQ: SLS) Before Investing. - Stocks Register
Geode Capital Management LLC Has $757,000 Position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
SELLAS advances cancer drug trials, eyes key 2025 milestones - Investing.com
SELLAS advances cancer drug trials, eyes key 2025 milestones By Investing.com - Investing.com UK
SELLAS Announces Key Business Objectives for 2025 - GlobeNewswire
SELLAS Life Sciences' Cancer Drug Shows 3x Better Survival Rate in Advanced Leukemia Study - StockTitan
State Street Corp Increases Stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET - GlobeNewswire
SELLAS Life Sciences Announces 2025 Corporate Strategy Call with CEO and Cancer Expert - StockTitan
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 17.6% in December - MarketBeat
62,785 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Acquired by XTX Topco Ltd - Defense World
United Rentals (URI-N) QuotePress Release - The Globe and Mail
SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia - Marketscreener.com
SELLAS Life Sciences Advances Phase 3 AML Trial - TipRanks
SELLAS triggers interim analysis in AML trial - Investing.com
SELLAS triggers interim analysis in AML trial By Investing.com - Investing.com Canada
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - GlobeNewswire
SELLAS Life Sciences Hits Major Milestone in Phase 3 AML Cancer Treatment Trial - StockTitan
SELLAS reports promising AML drug trial results By Investing.com - Investing.com Canada
SELLAS reports promising AML drug trial results - Investing.com India
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML - The Manila Times
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
2.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):